Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001210

Tobramycine

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

Nébramycine (facteur 6), O-[3-Amino-3-déoxy-α-D-glucopyranosyl-(1→6)]-O-[2,6-diamino-2,3,6-tridéoxy-α-D-ribohexopyranosyl-(1→4)]-2-déoxy-D-streptamine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H37N5O9
Numéro CAS:
32986-56-4
Poids moléculaire :
467.51
Numéro Beilstein :
1357507
Numéro MDL:
MFCD00077885
Code UNSPSC :
41116107
ID de substance PubChem :
329831309
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

tobramycin

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O

InChI

1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1

Clé InChI

NLVFBUXFDBBNBW-SNGYORCQSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Tobramycin for identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Actions biochimiques/physiologiques

La tobramycine est un aminoglycoside.
Mode d′action : Se lie à la sous-unité ribosomale 70S ; inhibe la translocation ; provoque des erreurs d′encodage.
Spectre d′activité : bactéries à Gram négatif. Non efficace contre les Enterococci.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361f

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Choose from one of the most recent versions:

Certificats d'analyse (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis.
The Medical letter on drugs and therapeutics, 55(1419), 51-52 (2013-06-26)
Kate McKeage
Drugs, 73(16), 1815-1827 (2013-11-07)
Inhaled tobramycin, an aminoglycoside antibacterial, has been in widespread use in the form of a nebulized solution against Pseudomonas aeruginosa for many years. More recently, tobramycin inhalation powder (TIP; TOBI(®) Podhaler(™)) was formulated using PulmoSphere(™) technology for administration as a
David E Geller et al.
Journal of aerosol medicine and pulmonary drug delivery, 24(4), 175-182 (2011-03-15)
Abstract At present, the only approved inhaled antipseudomonal antibiotics for chronic pulmonary infections in patients with cystic fibrosis (CF) are nebulized solutions. However, prolonged administration and cleaning times, high administration frequency, and cumbersome delivery technologies with nebulizers add to the
C L Bonsignore
Pediatric nursing, 24(3), 258-259 (1999-02-13)
Inhaled tobramycin was recently approved by the FDA in a 300 mg formulation for inhalation. The new product, manufactured by PathoGenesis Corporation, is referred to as TOBI and is indicated for cystic fibrosis patients with Pseudomonas aeruginosa. The advantage of
Susan M Cheer et al.
Drugs, 63(22), 2501-2520 (2003-11-12)
Specifically formulated for nebulisation using the PARI LC PLUS reusable nebuliser, tobramycin solution for inhalation (TSI) [TOBI] provides a high dose of tobramycin (an aminoglycoside antibacterial with good activity against Pseudomonas aeruginosa) to the lungs of patients with cystic fibrosis
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique